<DOC>
	<DOCNO>NCT01830361</DOCNO>
	<brief_summary>To assess efficacy tyrosine-kinase inhibitor midostaurin c-KIT FLT3-ITD mutate ( 8 ; 21 ) AML . To assess efficacy midostaurin depend type c-KIT mutation</brief_summary>
	<brief_title>Trial Assess Efficacy Midostaurin ( PKC412 ) Patients With c-KIT FLT3-ITD Mutated ( 8 ; 21 ) AML</brief_title>
	<detailed_description>AML patient display ( 8 ; 21 ) relatively favourable outcome . Nevertheless , approximately 50 % patient carry cytogenetic aberration alive 5 year . This suggest patient aggressive leukemic phenotype indicate need treatment optimization novel therapy . The mutated KIT gene well FLT3-ITD mutation recently identify factor likely explain heterogeneous clinical outcome within group ( 8 ; 21 ) AML . The FLT3 c-KIT gene encode type III receptor tyrosine kinase ( RTK ) important partly redundant function early hematopoietic stem cell . Various activate mutation describe gene . For c-KIT , incidence range 17 48 % depend source population type mutation determine . It consistently show AMLs ( 8 ; 21 ) , mutate c-KIT associate dramatically increase risk relapse reduce overall survival compare unmutated counterpart . The FLT3-ITD mutation similar negative effect prognosis patient group ( 8 ; 21 ) mutate AMLs c-KIT . PKC412 ( midostaurin ) know inhibit c-KIT RTK activity well FLT3 kinase , patient ITD TKD mutation . It therefore possible abrogate negative impact pathologically increase c-KIT FLT3-ITD activity relapse overall survival use midostaurin patient population . Aim propose clinical trial prove efficacy midostaurin c-KIT FLT3-ITD mutate ( 8 ; 21 ) - AMLs open-label one-arm design .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Diagnosis cKIT mutate ( 8 ; 21 ) AML i.e . 1 . &gt; 20 % myeloid blast bone marrow and/or peripheral blood initial diagnosis 2 . Plus cytogenetic diagnosis aberration ( 8 ; 21 ) /AML1ETO 3 . Plus mutation cKIT gene ( mutKIT17 mutKIT8 ) FLT3ITD mutation cKIT FLT3ITD mutation Chemoresponsive disease determine early bone marrow assessment day 1416 first cycle induction therapy cytarabine combination daunorubicine idarubicine , mitoxantrone Fit intensive chemotherapy Age 1865 year ECOG performance status 02 Life expectancy least 12 week Primary refractory previously relapse AML Noneligibility highdose cytarabine base consolidation , e.g . intolerance cytarabine Inability swallow oral medication Symptomatic congestive heart failure Bilirubin &gt; 2.5 x upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>c-KIT</keyword>
	<keyword>FLT3-ITD</keyword>
	<keyword>( 8 ; 21 )</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>midostaurin</keyword>
</DOC>